Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

2 weeks ago

Alignmt LLC

Whether your company is only but a fledgling startup or you happen to be a mogul already, you must always be able to prepare reliable financial projections to maintain financial health, identify new opportunities for incredibly profitable customer retention and continually grow your business. buff.ly/2FBD5Xf ... See MoreSee Less

View on Facebook

2 weeks ago

Alignmt LLC

The end goal? To be able to effectively come up with a systematic process that ensures you get that elusive opportunity everybody’s vying for: the chance to ignite consistent, sustainable revenue growth that can be shaped and changed by different tactics and industry trends. buff.ly/2NfQ2u3 ... See MoreSee Less

View on Facebook

2 weeks ago

Alignmt LLC

What are your current goals? buff.ly/35vkBBW

#alignmentmap
... See MoreSee Less

View on Facebook

2 weeks ago

Alignmt LLC

Creating value is your number one priority. buff.ly/2SXXBZH

#alignmentmap
... See MoreSee Less

View on Facebook

2 weeks ago

Alignmt LLC

Who should dive into preparing financial projections? Every single business leader alive today. buff.ly/2T4b5n3

#alignmentmap
... See MoreSee Less

View on Facebook

3 weeks ago

Alignmt LLC

All exercise is good exercise. It's why you practice. To perform with consistency when it matters. The more everyone on your team understands why they're on the team the more you will grow. buff.ly/2N3zipI

#alignmentmap
... See MoreSee Less

View on Facebook

3 weeks ago

Alignmt LLC

Encouraging accountability is good for everyone in your organization. And it's all within reach. buff.ly/2N0QRqt

#alignmentmap
... See MoreSee Less

View on Facebook

3 weeks ago

Alignmt LLC

Every one of your staff wants to and can contribute to your organization’s success—empower them! buff.ly/37KcnY7 ... See MoreSee Less

View on Facebook

3 weeks ago

Alignmt LLC

What myth about business valuation has cost you the most? buff.ly/2T4igLE ... See MoreSee Less

View on Facebook

3 weeks ago

Alignmt LLC

Business valuation is an important metric at a lot of times during your business life cycle. Which is the most important to you? buff.ly/39FZhNr ... See MoreSee Less

View on Facebook

Check out my latest article: Buy-Side M&A Strategy: Financing an Acquisition https://www.linkedin.com/pulse/buy-side-ma-strategy-financing-acquisition-ian-shanno via @LinkedIn

Corporate: a professional approach to business
Finance: about the future
Consulting: tapping outside expertise for corporate finance excellence
https://alignmt.com

Check out my latest article: Investor Presentation Tips: 11 Steps to Writing an Effective Investor Deck https://www.linkedin.com/pulse/investor-presentation-tips-11-steps-writing-effective-ian-shanno via @LinkedIn

Load More...

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130

+1 (858) 617-7600

www.neurocrine.com

January 2020
S M T W T F S
« Nov    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account